Showing results (141-150 of 167) with videos related to
Sort By:
Pageof 17
The New England Journal of Medicine|June 26, 2003
The influence of finasteride on the development of prostate cancerIan M Thompson, Phyllis J Goodman, Catherine M Tangen, et al.The New England Journal of Medicine|June 4, 2010
Longer therapy, iatrogenic amenorrhea, and survival in early breast cancerSandra M Swain, Jong-Hyeon Jeong, Charles E Geyer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2011
Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trialPatricia A Ganz, Stephanie R Land, Charles E Geyer, et al.Oncology|May 6, 2021
BRCA1 Protein Expression Predicts Survival in Glioblastoma Patients from an NRG Oncology RTOG CohortMaria Vassilakopoulou, Minhee Won, Walter J Curran, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 1999
Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25B Fisher, S Anderson, A DeCillis, et al.The Lancet. Oncology|October 8, 2013
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trialAndré Robidoux, Gong Tang, Priya Rastogi, et al.JNCI Cancer Spectrum|April 8, 2020
Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance)Justin C Brown, Sui Zhang, Fang-Shu Ou, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 14, 2013
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trialSandra M Swain, Gong Tang, Charles E Geyer, et al.Breast Cancer Research and Treatment|November 9, 2013
Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43Kalliopi P Siziopikou, Stewart J Anderson, Melody A Cobleigh, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2019
NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2Louis Fehrenbacher, Reena S Cecchini, Charles E Geyer, et al.Pageof 17